[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356191-105":59,"doc-detail-356191-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-current-landscape-of-pulmonary-hypertension-in-myeloproliferative-neoplasms","The Current Landscape of Pulmonary Hypertension in Myeloproliferative Neoplasms","","Pulmonary hypertension (PH) is an increasingly recognized complication in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), carrying important implications for both cardiovascular morbidity and mortality and for hematologic progression. Shared pathophysiologic mechanisms link PH with MPNs, and improved survivorship with reduced overall disease progression has shifted the epidemiology toward higher incidence and prevalence of concurrent and/or subsequent cardiovascular disease. Prospective studies are needed to refine screening protocols, risk stratification, and prognostic and therapeutic relevance of PH in this population.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-current-landscape-of-pulmonary-hypertension-in-myeloproliferative-neoplasms/356191/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-current-landscape-of-pulmonary-hypertension-in-myeloproliferative-neoplasms/356191.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is pulmonary hypertension important in myeloproliferative neoplasms?","Question",{"text":112,"@type":113},"Pulmonary hypertension is linked to cardiovascular morbidity and mortality and to hematologic progression, including risks of disease worsening. It also shares underlying mechanisms with MPN biology.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is pulmonary hypertension defined for clinical diagnosis in this review?",{"text":117,"@type":113},"The review cites the ESC/ERS 2022 PH guidelines, defining PH by mean pulmonary artery pressure > 20 mmHg at rest measured by right heart catheterization.",{"name":119,"@type":110,"acceptedAnswer":120},"What role does echocardiography play in evaluating PH in MPN patients?",{"text":121,"@type":113},"Transthoracic echocardiography is described as the main noninvasive approach for screening, risk stratification, and identifying which patients need further invasive hemodynamic evaluation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356191,1790781896,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Review  \nThe Current Landscape of Pulmonary Hypertension in Myeloproliferative Neoplasms  \nMonica Ferrante 1, Hyeon-Ju Ali 2, Gabriela Hobbs 3 and Orly Leiva 1, *  \nAcademic Editor: Francesc Solé  \nReceived: 1 July 2026  \nRevised: 16 August 2026  \nAccepted: 24 August 2026  \nPublished: 26 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Gill Heart and Vascular Institute, University of Kentucky College of Medicine, Lexington, KY 40536, USA; [monica.ferrante@uky.edu](monica.ferrante@uky.edu)  \n2 Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; [hrali@mdanderson.org](hrali@mdanderson.org)  \n3 Department of Hematology & Oncology, Mass General Brigham Cancer Institute, Massachusetts General Hospital & Harvard Medical School, Boston, MA 02114, USA; [ghobbs@mgb.org](ghobbs@mgb.org)  \n* Correspondence: oleiva@bu.edu or orly.leiva@uky.edu  \nSimple Summary  \nPulmonary hypertension (PH), or elevated blood pressure in the pulmonary vasculature, isan increasingly recognized yet still underdiagnosed cardiovascular complication among patients with myeloproliferative neoplasms (MPNs) . Currently, there are no standardized protocols for the diagnosis of PH in MPN patients. This review explores the mechanisms by which PH develops in MPN patients, how to approach screening, and the consequences on patient outcomes. Recent data suggest MPN patients with PH face up to a threefold higher risk of disease progression to leukemia and increased risk of major cardiovascular events (MACE) . Whether earlier and systematic screening for PH in MPN patients is important is a question for future prospective studies.  \nAbstract  \nPulmonary hypertension (PH) is an increasingly recognized complication of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) . Recent data suggest prognostic implications of both cardiovascular morbidity and mortality and hematologic progression. Additionally, PH and MPNs share common pathophysiologic mechanisms that bridge these two seemingly different disorders. The landscape of PH in MPNs is evolving in the face of improved survivorship and reduced disease progression, leading to increased incidence and prevalence of concurrent and/or consequent cardiovascular disease. Prospective studies are necessary to refine screening protocols, risk stratification, and prognostic and therapeutic implications of PH in this population.  \nKeywords: myeloproliferative neoplasm; pulmonary hypertension; cardio-oncology; polycythemia vera; essential thrombocythemia; myelofibrosis; heart failure  \n1. Introduction  \nThe Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are aheterogenous group of clonal hematopoietic disorders that include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) [1] . Patients with MPNs are at increased risk of cardiovascular complications, including arterial and venous thrombosis, heart failure (HF), and pulmonary hypertension (PH) [2] . While the focus of cardiovascular disease research and clinician attention has been directed towards thrombosis, emerging evidence suggests that non-thrombotic cardiovascular complications (including HF and  \nPH) are common and are associated with not only cardiovascular morbidity and mortality, but also hematologic progression and prognosis [2] . The landscape of cardio-oncology and MPNs is evolving in the face of earlier diagnosis, improved survivorship, and reduction in disease progression, ultimately driving increased incidence and prevalence of concurrent or consequent cardiovascular disease [3] .  \nPulmonary hypertension is an increasingly recognized complication across Philadelphianegative MPN subtypes [2]. There is growing clinical salience given its prognostic implications for both major adverse car","cbCair8SGj4xIvxs","https://ap.wps.com/l/cbCair8SGj4xIvxs","pdf",608533,11,"English","# Introduction\n## Pulmonary Hypertension Epidemiology and Hemodynamic Classification\n# Prognostic and Clinical Implications in MPNs","[{\"question\":\"Why is pulmonary hypertension important in myeloproliferative neoplasms?\",\"answer\":\"Pulmonary hypertension is linked to cardiovascular morbidity and mortality and to hematologic progression, including risks of disease worsening. It also shares underlying mechanisms with MPN biology.\"},{\"question\":\"How is pulmonary hypertension defined for clinical diagnosis in this review?\",\"answer\":\"The review cites the ESC/ERS 2022 PH guidelines, defining PH by mean pulmonary artery pressure \\u003e 20 mmHg at rest measured by right heart catheterization.\"},{\"question\":\"What role does echocardiography play in evaluating PH in MPN patients?\",\"answer\":\"Transthoracic echocardiography is described as the main noninvasive approach for screening, risk stratification, and identifying which patients need further invasive hemodynamic evaluation.\"}]","The Current Landscape of Pulmonary Hypertension in Myeloproliferative Neoplasms | PDF",1790123960,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e304535e287bfaa8c063b51a27b2f755.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19f636259ca13d715e64613a828f55bb.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81aebf85606cabeb4a88dd29290d1db5.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4755b7f0d64e810b3fb707221965f39a.webp",980,1385]